ANI PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ANI PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $47.97M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $51.34M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $54.36M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $52.89M | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $57.12M | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | $50.70M | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | $47.27M | Feb 27, 2020 |
| FY2019 | Mar 31, 2018 | $46.48M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $47.29M | Feb 27, 2019 |
| FY2018 | Sep 30, 2017 | $48.16M | Feb 27, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $883.37M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $614.38M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $486.82M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $316.39M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $216.14M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $57.25M | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | $52.98M | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | $48.47M | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | $49.77M | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $47.97M | Mar 11, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.34M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($18.52M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $18.78M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($47.90M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($42.60M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($3.64M) | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | $434.0K | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | ($12.34M) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | ($7.01M) | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | ($4.84M) | Mar 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.09M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $584.0K | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $46.97M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($35.28M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($39.79M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $331.0K | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | $2.80M | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | ($11.31M) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | ($7.84M) | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | ($4.67M) | Mar 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.66M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $44.58M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $34.29M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $22.32M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $11.37M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $16.00M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $19.81M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $15.39M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $9.07M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $2.91M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $317.75M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $249.64M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $161.70M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $124.04M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $84.29M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $64.99M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $55.84M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $44.06M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $31.58M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $27.83M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.23M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $64.02M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $118.96M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($31.20M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.32M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $15.27M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $45.63M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $67.07M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $39.42M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $27.47M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.84M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $16.24M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $8.87M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $8.88M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $2.56M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $6.14M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $6.64M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $5.74M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $10.37M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $4.57M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.28B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $904.42M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $760.09M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $771.60M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $461.19M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $456.79M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $430.60M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $412.14M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $322.86M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $899.65M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $855.94M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $446.82M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $421.55M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $412.86M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $265.49M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $244.00M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $233.34M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $237.38M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $153.22M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $540.72M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $403.68M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $432.75M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $313.69M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $333.89M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $195.70M | Mar 15, 2022 |
| FY2021 | Dec 31, 2019 | $212.79M | Mar 15, 2022 |
| FY2021 | Dec 31, 2018 | $197.26M | Mar 15, 2022 |
| FY2020 | Dec 31, 2017 | $174.76M | Mar 11, 2021 |
| FY2019 | Dec 31, 2016 | $169.65M | Feb 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.48M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $59.99M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $28.22M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $28.22M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $27.89M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $3.58M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $3.58M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $3.58M | Feb 27, 2020 |
| FY2019 | Dec 31, 2017 | $1.84M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.84M | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.10M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($100.28M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($80.13M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($97.29M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($47.77M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($4.97M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $17.58M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $11.49M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($4.01M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($2.92M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.59M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $144.86M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $221.12M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $48.23M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $100.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $7.86M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $62.33M | Mar 9, 2023 |
| FY2021 | Dec 31, 2018 | $43.01M | Mar 15, 2022 |
| FY2020 | Dec 31, 2017 | $31.14M | Mar 11, 2021 |
| FY2019 | Dec 31, 2016 | $27.37M | Feb 27, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $128.21M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $120.64M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $113.43M | Mar 2, 2017 |
| FY2015 | Dec 31, 2014 | $106.54M | Feb 23, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 11, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 11, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22.49M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 21.11M | Feb 27, 2026 |